About two-thirds of all participants reported at least one gastrointestinal adverse event
Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., Yanase, T., et al
These solutions' market penetration in Germany helps regional clinical research organizations (CROs) with their clinical research trials and assures managerial simplicity, which speeds up the discovery process
Bhatia K., Elmarakby A
Intra and inter-assay CV was 2.2% and 4.5%, respectively
Rather than injecting patients with a weakened virus or proteins from the pathogen that our immune systems can recognize, which is whats typically done when we get a flu vaccine, the new vaccines from Moderna and Pfizer -- the two that made it to the market first in the U.S